Navigation Links
Celtaxsys Acquires Clinical Stage Innate Immunity Drug for Inflammation
Date:1/5/2012

ltaxsys is a privately held biotechnology company focused on the discovery, development, and commercialization of innovative pharmaceutical products for the treatment of inflammatory and autoimmune diseases. Celtaxsys was founded in 2005 as an early stage drug discovery company specializing in innate immune response and the Company's platform is designed to capture the synergy between three key scientific areas of discovery: Innate Immunity; The Neutrophil; and the treatment of Inflammatory Disease. Celtaxsys has offices in San Francisco, California and Atlanta, Georgia. For more information and corporate background, please visit www.celtaxsys.com.

About Estrellita

Estrellita is a privately held San Francisco Bay Area company that acquired the rights to the small molecule LTA4H inhibitor, EP-501, from a major pharmaceutical company. The company, led by Dr. William Guilford, was developing the novel orally-available drug as a potential safe and effective treatment for a wide range of chronic inflammatory diseases.

Forward Looking Statements

Statements included in this press release that are not a description of historical facts may be forward looking statements.  The inclusion of forward looking statements should not be regarded as a representation by Celtaxsys that any of its plans will be achieved.  Actual results may differ materially from those anticipated or set forth in this press release due to the risks and uncertainties inherent in Celtaxsys's business including, without limitation, statements about difficulties or delays in developing, obtaining regulatory approval, manufacturing and commercializing its products, unexpected performance or side effects of its products, the scope and validity of its products' patent protection, competition from other companies and its ability to obtain additional financing to support its operations.  All forward looking statements are qua
'/>"/>

SOURCE Celtaxsys, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Dr. Michael Hanley Joins Celtaxsys as CEO
2. Dr. H. Daniel Perez Joins Celtaxsys Board of Directors
3. Duff & Phelps Acquires Lumin Expert Group To Build Global Intellectual Property Practice
4. Safecor Health Acquires Unit-Dose Pharmaceutical Leader RSC
5. Arisyn Therapeutics Inc. Acquires Highly Novel Portfolio of Therapeutic Small Molecules for Infectious Disease and Cancer
6. MediCult Acquires US-Based MidAtlantic Diagnostics to Further Strengthen ART Presence
7. Milestone Scientific Acquires Additional Patent Rights for Painless Injections and Resolves Related Litigations
8. Advanced Instruments Acquires D & F Control Systems Inc.
9. Circassia Acquires North American and Japanese Rights to Dopexamine
10. CPA Acquires Renowned German Patent Research Specialist, SVPG
11. Millstone Medical Outsourcing Acquires New Facility to Accommodate Growing Business, Provide Additional Clean Room Capacity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2015)... Innovative biomass supply chain industry leader, ... sponsorship of the first annual Advanced Bioeconomy Feedstocks ... Hotel in New Orleans, June 9-10, the conference brings ... to further the advancements of feedstock by discussing pressing ... logistics, yield improvement and more. , As ...
(Date:6/3/2015)... Marktech Optoelectronics is pleased to introduce a new ... internal gain mechanism, fast time response, low dark current ... APD’s are recommended for applications that require high bandwidth, ... pre-amp noise. In addition, Marktech APD's provide higher sensitivity ... low-level light detection and short pulse detection. , ...
(Date:6/3/2015)... CARDIFF, UK, and BRUSSELS, Belgium (PRWEB) June 03, 2015 ... safety and beyond, photonics plays an important part in ... by the European Commission. Innovation and technology leaders helped ... photonics in thematic sessions during the Photonics21 annual ... was a sponsor of the event, held 28 ...
(Date:6/2/2015)... Global Stem Cells Group subsidiary Adimarket has ... products for the regeneration and repair of human organs and ... Group’s ambitious expansion plans in Latin America, a commitment made ... medicine and stem cell therapies. , Bioquark Inc. ... the ability to alter the regulatory state of human tissues ...
Breaking Biology Technology:Genera to Sponsor Advanced Bioeconomy Feedstocks Conference 2015 2Genera to Sponsor Advanced Bioeconomy Feedstocks Conference 2015 3Marktech Introduces New Line of APDs 2Photonics21 Annual Meeting Focuses on Solutions for ‘Societal Challenges’ 2Photonics21 Annual Meeting Focuses on Solutions for ‘Societal Challenges’ 3Adimarket Named Latin American Distributor for Bioquark Biologic Products for the Regeneration and Repair of Human Organs and Tissue with Stem Cells 2Adimarket Named Latin American Distributor for Bioquark Biologic Products for the Regeneration and Repair of Human Organs and Tissue with Stem Cells 3
... ... ... 2010 -- ProRepro today announced it has become an Autodesk authorized value-added reseller (VAR). ... Southern California. ProRepro’s qualified staff demonstrates in-depth technical and industry knowledge and a commitment ...
... INDIANAPOLIS and WALTHAM, Mass. , May 6, 2010 ... Company (NYSE: LLY ) and Alkermes, Inc. (Nasdaq: ALKS ... classified the BYDUREON™ (exenatide for extended-release injectable suspension) complete response as a ... (PDUFA) action date of October 22, 2010 . , ...
... May 6 /PRNewswire-FirstCall/ - Aeterna Zentaris Inc. ( ... company specialized in oncology and endocrinology, today announced that ... Administration (FDA), orphan-drug designation for AEZS-108, its doxorubicin targeted ... is currently in a Phase 2 trial in advanced ...
Cached Biology Technology:ProRepro Becomes a Value-Added Reseller for Autodesk 2BYDUREON (TM) FDA Review Timeline Set with PDUFA Action Date of October 22, 2010 2BYDUREON (TM) FDA Review Timeline Set with PDUFA Action Date of October 22, 2010 3BYDUREON (TM) FDA Review Timeline Set with PDUFA Action Date of October 22, 2010 4BYDUREON (TM) FDA Review Timeline Set with PDUFA Action Date of October 22, 2010 5BYDUREON (TM) FDA Review Timeline Set with PDUFA Action Date of October 22, 2010 6BYDUREON (TM) FDA Review Timeline Set with PDUFA Action Date of October 22, 2010 7BYDUREON (TM) FDA Review Timeline Set with PDUFA Action Date of October 22, 2010 8Aeterna Zentaris Receives Orphan-Drug Designation from the FDA for AEZS-108 in Ovarian Cancer 2Aeterna Zentaris Receives Orphan-Drug Designation from the FDA for AEZS-108 in Ovarian Cancer 3
(Date:5/21/2015)... The Sync Project™ , a global collaboration harnessing ... a collaborative partnership with Berklee,s Institute for Creative ... on original research, joint course development and an internship ... Sync Project and BerkleeICE are exploring the launch of ... academic year.  The course will focus ...
(Date:5/19/2015)... Fingerprint Cards (FPC) has received an ... and FPC1035 from one if its module partners. Deliveries are ... 2015 and the sensors will be used by smartphone manufacturers ... 2015 hereby amount to 740 MSEK to date. In addition ... and a number of smaller orders not separately communicated amounting ...
(Date:5/18/2015)... May 18, 2015 Fingerprint Cards (FPC) ... FPC1025, FPC1145, FPC1155 and FPC1035 from one if its module ... and including Q3 2015 and the sensors will be used ... order values for 2015 hereby amount to 740 MSEK to ... of 140 MSEK and a number of smaller orders not ...
Breaking Biology News(10 mins):The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 2The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 3Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2
... University of Texas at San Antonio will bring together ... countries when it hosts the inaugural UTSA North American ... Building at the UTSA Downtown Campus. The summit will ... Canada and Mexico addressing the energy needs for future ...
... A novel cell therapy using retinal pigment epithelial ... implanted in the brain can improve the symptoms ... (PD). Rush University Medical Center neurosurgeon Dr. ... University, Atlanta found the therapy Spheramine was well-tolerated ...
... safer along Massachusetts Bay,s busy shipping lanes this spring, ... buoys recognize whales, distinctive calls and route the information ... system, giving ships the chance to avoid deadly collisions. ... >) -- developed at the Cornell Lab of Ornithology ...
Cached Biology News:UTSA hosts North American Energy Summit May 1-2 2Cell-based therapy shows promise in patients with Parkinson's disease 2Cell-based therapy shows promise in patients with Parkinson's disease 3Warning buoys for right whales installed along Massachusetts Bay 2
... Immobilized] Goat Immunogen: Goats ... (MASMTGGQQMG). Antibody was isolated by affinity ... support. Goat anti- human T7 affinity purified ... cyanogens bromide method. Specificity: ...
C/EBPdelta Antibody Shipping Temperature: Cold Storage Temperature: -20C...
Mouse monoclonal [11C9] to Zeralenone ( Abpromise for all tested applications). Antigen: Chemical / Small Molecule conjugated to BSA: Zeralenone...
Anti-human C5a/C5a des-Arg (neo-epitode), Clone 2952, Monoclonal Antibody...
Biology Products: